PPT-HER2 TESTING IN BREAST CANCER

Clinical Practice Guideline Update American Society of Clinical Oncology College of American Pathologists wwwascoorgguidelines American Society of Clinical Oncology  All rights reserved. Leisha. A. . Emens. , M.D., . Ph.D. Associate Professor . of Oncology . Tumor . Immunology and Breast . Cancer . Research . Programs. Johns Hopkins University. Conflict of Interest Statement. Biosante. Clinical Practice Guideline Update. American Society of Clinical Oncology /. College of American Pathologists . www.asco.org/guidelines/. © American . Society of Clinical Oncology®.  All rights reserved.. First . Line and Beyond. Moderator:. Joseph Gligorov, MD, . PhD . Head, Cancer . Coordination Center . HUEP. University . Cancer . Institute. Sorbonne University. Paris. , . France. Panelist:. Carlos H. Barrios, . Gradishar. . MD, FACP. Betsy . Bramsen. Professor of Breast Oncology. Director, Maggie Daley Center For Women's Cancer Care. Robert H. Lurie Comprehensive Cancer Center. Northwestern University Feinberg School of Medicine. Monica Brown, MPH, PhD. . California Cancer Registry. Mary Paré, RN, BS. . Sutter Cancer Center, Sacramento. Katrina Bauer, MS, CTR. . California Cancer Registry. NAACCR 2009 Conference, June 13-19, San Diego. Jennifer M. Matro, MD. Rena Rowan Breast Center. Abramson Cancer Center. University of Pennsylvania. Overview. What is metastatic breast . c. ancer (MBC)?. Who is at risk?. Subtypes of Breast Cancer. Mohammad . Jahanzeb. , MD, FACP. Professor of Clinical Medicine, Hematology-Oncology. Director, UM Sylvester Deerfield Campus. Associate Center Director for Community Outreach. Sylvester Comprehensive Cancer Center. Management of HER2 Over-Expressed Breast Cancer in the Adjuvant, Neoadjuvant, and Metastatic settings Christy A Russell, MD Keck School of Medicine University of Southern California Metastatic Breast Cancer A. University of Tennessee Medical Center – Knoxville. Departments of Pathology, Surgery, and Medicine. BREAST CANCER IN YOUNG AGE (≤40 YEARS): THE UNIVERSITY OF. . TENNESSEE MEDICAL CENTER AT KNOXVILLE 10 YEAR EXPERIENCE. in Development for . Breast Cancer. Sara A. Hurvitz, MD, FACP. Professor of Medicine. David Geffen School of Medicine, UCLA. Los Angeles, CA. William J. Gradishar, MD, FASCO, FACP. Betsy Bramsen Professor of Breast Oncology & Professor of Medicine. . Breast Cancer | . Epidemiology- Australia. Australian Institute of Health and Welfare 2014. ACIM (Australian Cancer Incidence and Mortality) Books. Canberra. AIHW. Overall is the third leading cause of cancer. Bidstrup. Mrs B is a 49 . yo. woman who attended for a regular 3 weekly review and Herceptin dose. Intro. Dec 2000: . attended GP regarding lump that had been present in L) breast for 6/12. . Bx. - breast ca. Lisa A. Carey MD, . ScM. University of North Carolina. Lineberger. Comprehensive Cancer Center.  .  . HER2-Positive Disease. Courtesy of Lisa Carey, MD. ExteNET. Background: . Final efficacy analysis of a trial that was the basis for approval of neratinib for extended adjuvant therapy in HER2-positive . Percent with Patients. Number of Patients (Median). ER-positive, HER2-negative breast cancer for whom you ordered a genomic assay. 92. 14. Metastatic ER-positive, HER2-negative . breast cancer. 96. 10.